Literature DB >> 30884980

Real-world impact of the high concentration non-avian high molecular weight hyaluronan on pain medication use among osteoarthritis patients.

Abhishek S Chitnis1, Katherine Etter2, Chantal E Holy1, F Scott Gray3, Fernando J Manalac4, Brad Bisson5, Samir K Bhattacharyya6.   

Abstract

Objective: A prior study found that hyaluronic acid (HA) treatment may help reduce pain medication use (such as steroids, non-steroidal anti-inflammatory drugs [NSAIDs] and opioids) among knee osteoarthritis (OA) patients in the real-world setting. This study aims to update the prior study results to include only the high concentration non-avian high molecular weight hyaluronan (HMW-HA) injectables using data from recent years.Study design: This was a retrospective cohort study utilizing IBM MarketScan Commercial data from 2008 to 2015.
Methods: Commercially insured patients between 18 and 64 years of age who received high concentration non-avian HMW-HA (Orthovisc1) between 1 January 2008 and 30 June 2015 were identified. Utilization of three prescription pharmacotherapies commonly used in the treatment for knee OA - NSAIDs, corticosteroid injections and opioids - in the 6 month pre and post periods was assessed. Utilization was measured as number of prescriptions and any prescription (yes/no). The independent variable was receiving the high concentration non-avian HMW-HA injection. Paired sample t-test and McNemar's test were used to assess pre-post changes.
Results: The utilization of NSAIDs and steroids prescriptions was reduced significantly during the post period among the study cohort. The proportion of patients filling these prescriptions during the post period was also reduced (p < .001). In addition, the number of patients getting any opioid prescriptions was reduced significantly during the post period (p < .001).Conclusions: Based on this retrospective cohort study, the high concentration non-avian HMW-HA may offer effective pain alleviation among knee OA patients while reducing prescription pain medications such as steroids, NSAIDs and opioids.

Entities:  

Keywords:  High concentration non-avian high molecular weight hyaluronan; osteoarthritis; pain medication; real-world data

Mesh:

Substances:

Year:  2019        PMID: 30884980     DOI: 10.1080/03007995.2019.1596670

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  5 in total

1.  Platelet-rich plasma (PRP) in osteoarthritis (OA) knee: Correct dose critical for long term clinical efficacy.

Authors:  Himanshu Bansal; Jerry Leon; Jeremy L Pont; David A Wilson; Anupama Bansal; Diwaker Agarwal; Iustin Preoteasa
Journal:  Sci Rep       Date:  2021-02-17       Impact factor: 4.379

Review 2.  Intra-articular Hyaluronic Acid for Osteoarthritis of the Knee in the United States: A Systematic Review of Economic Evaluations.

Authors:  Margaret Mordin; William Parrish; Catherine Masaquel; Brad Bisson; Catherine Copley-Merriman
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2021-11-19

3.  Evaluation of Hylan G-F 20 Treatment with Opioid Prescriptions and Intraarticular Corticosteroid Injections in Patients with Osteoarthritis of the Knee Using a Claims Database.

Authors:  Michael J Langworthy; Charles D Hummer; Wilson Ngai; Lichen Hao; David Webner
Journal:  Cartilage       Date:  2020-10-23       Impact factor: 4.634

4.  Association Between Bio-Fermentation Derived Hyaluronic Acid and Healthcare Costs Following Knee Arthroplasty.

Authors:  Mathew Nicholls; Faizan Niazi; Winnie W Nelson; Edmund Lau; Steven M Kurtz; Kevin L Ong
Journal:  Clinicoecon Outcomes Res       Date:  2022-08-30

Review 5.  Intraarticular Hyaluronic Acid Preparations for Knee Osteoarthritis: Are Some Better Than Others?

Authors:  David Webner; Yili Huang; Charles D Hummer
Journal:  Cartilage       Date:  2021-05-28       Impact factor: 4.634

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.